LABMASTER RAISES €6M IN FUNDING
Labmaster
Ltd, a Turku, Finland based biotechnology company raises €6M from a
Korean
company for the development of next generation proprietary
detection
technology.
Labmaster is developing new
technology for clinical, biochemical and
chemical analysis based
on cathodic electrochemiluminescence (CECL). This
technology
relates to the electrical excitation of label
substance/substances
by hot electrons. Reactions occur on silicon based
electrodes
coated with an insulating layer and utilize the
resulting
electrochemiluminescence in analytical applications,
especially in
bioaffinity assays such as immunoassays and
DNA-probe assays.
One of the advantages of this technology is
cost effectiveness achieved by
replacing expensive optics with low
priced sophisticated electronics. This
technology is suitable for
many kinds of laboratory instrumentation
applications, for example
in clinical diagnostics from batch size analyzers
to disposable
rapid tests (POCT). Labmaster owns the immaterial property rights
for
this technology and has the strategy to further protect its
findings related
to new applications.
<< Back
